HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.0000000001 from 426 studies, used in 59 countries.
No treatment is 100% effective.
Protocols combine treatments.
In vitro analysis showing that HCQ efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of HCQ and a TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone.
41 preclinical studies support the efficacy of HCQ for COVID-19:
1.
Shang et al., Identification of Cathepsin L as the molecular target of hydroxychloroquine with chemical proteomics, Molecular & Cellular Proteomics, doi:10.1016/j.mcpro.2025.101314.
2.
González-Paz et al., Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data, ACS Omega, doi:10.1021/acsomega.3c06968.
3.
Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.
4.
Guimarães Silva et al., Are Non-Structural Proteins From SARS-CoV-2 the Target of Hydroxychloroquine? An in Silico Study, ACTA MEDICA IRANICA, doi:10.18502/acta.v61i2.12533.
5.
Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.
7.
Yadav et al., Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine and Oseltamivir as a Potential Inhibitor Against SARS-CoV-2: A Computational Study, Research Square, doi:10.21203/rs.3.rs-628277/v1.
8.
Hussein et al., Molecular Docking Identification for the efficacy of Some Zinc Complexes with Chloroquine and Hydroxychloroquine against Main Protease of COVID-19, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129979.
9.
Baildya et al., Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129891.
10.
Noureddine et al., Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: molecular docking and DFT calculations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2020.101334.
11.
Tarek et al., Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention, European Journal of Drug Metabolism and Pharmacokinetics, doi:10.1007/s13318-020-00640-6.
12.
Rowland Yeo et al., Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1955.
13.
Pinatel et al., SARS-CoV-2 infects human primary cytotrophoblasts mainly through a non-canonical entry route, Molecular Human Reproduction, doi:10.1093/molehr/gaag015.
14.
Hitti et al., Hydroxychloroquine attenuates double-stranded RNA-stimulated hyper-phosphorylation of tristetraprolin/ZFP36 and AU-rich mRNA stabilization, Immunology, doi:10.1111/imm.13835.
15.
Yan et al., Super-resolution imaging reveals the mechanism of endosomal acidification inhibitors against SARS-CoV-2 infection, ChemBioChem, doi:10.1002/cbic.202400404.
16.
Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.
17.
Alsmadi et al., The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel, AAPS PharmSciTech, doi:10.1208/s12249-023-02627-3.
18.
Wen et al., Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells, Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjad048.
19.
Kamga Kapchoup et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382.
20.
Milan Bonotto et al., Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection, Antiviral Research, doi:10.1016/j.antiviral.2023.105655.
21.
Miao et al., SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells, Cell Chemical Biology, doi:10.1016/j.chembiol.2023.02.001.
22.
Yuan et al., Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture, Communications Biology, doi:10.1038/s42003-022-03841-8.
23.
Jitobaom et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.
24.
Faísca et al., Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2, Pharmaceutics, doi:10.3390/pharmaceutics14040877.
25.
Delandre et al., Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, Pharmaceuticals, doi:10.3390/ph15040445.
26.
Purwati et al., An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia, PLOS One, doi:10.1371/journal.pone.0252302.
27.
Zhang et al., SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination, Cell Death & Differentiation, doi:10.1038/s41418-021-00782-3.
28.
Dang et al., Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein, bioRxiv, doi:10.1101/2021.03.16.435741.
29.
Shang (B) et al., Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice, Virology Journal, doi:10.1186/s12985-021-01515-1.
30.
Wang et al., Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus, Phytomedicine, doi:10.1016/j.phymed.2020.153333.
31.
Sheaff, R., A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity, bioRxiv, doi:10.1101/2020.08.02.232892.
32.
Ou et al., Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2, PLOS Pathogens, doi:10.1371/journal.ppat.1009212.
33.
Andreani et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
34.
Clementi et al., Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro, Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704.
35.
Liu et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discovery 6, 16 (2020), doi:10.1038/s41421-020-0156-0.
36.
Yao et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237.
Ou et al., 22 Jul 2020, peer-reviewed, 6 authors.
In vitro studies are an important part of preclinical research, however results may be very different in vivo.
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
PLOS Pathogens, doi:10.1371/journal.ppat.1009212
Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This compound is known to interfere with endosomal acidification necessary to the proteolytic activity of cathepsins. Following receptor binding and endocytosis, cathepsin L can cleave the SARS-CoV-1 and SARS-CoV-2 spike (S) proteins, thereby activating membrane fusion for cell entry. The plasma membrane-associated protease TMPRSS2 can similarly cleave these S proteins and activate viral entry at the cell surface. Here we show that the SARS-CoV-2 entry process is more dependent than that of SARS-CoV-1 on TMPRSS2 expression. This difference can be reversed when the furincleavage site of the SARS-CoV-2 S protein is ablated or when it is introduced into the SARS-CoV-1 S protein. We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone. These studies identify functional differences between SARS-CoV-1 and -2 entry processes, and provide a mechanistic explanation for the limited in vivo utility of hydroxychloroquine as a treatment for COVID-19.
media containing 2% FBS. Same infection procedures were applied on other cell lines without the plate coating and transfection steps.
Cell surface expression and S protein analysis To measure surface TMPRSS2 expression of 293T-ACE2 transiently transfected with TMPRSS2 and the stable cell line 293T/ACE2/TMPRSS2, cells were detached by 1mM EDTA in PBS and then stained by 2 ug/ml of anti-Flag M2 antibody (Sigma-Aldrich, F1804) and 2 μg/ml of goat anti-mouse IgG (H+L) conjugated with Alexa 647 (Jackson ImmunoResearch Laboratories, #115-606-146). Flow cytometry analysis was done using Accuri C6 (BD Biosciences). To measure the endogenous TMPRSS2 expression of Vero, H1299, H1975 and Calu-3 cells, cells were permeabilized with PBS including 0.5% Triton X-100 (Sigma-Aldrich) at room temperature for 10 min, and detected by 2 μg/ml monoclonal rabbit Anti-TMPRSS2 antibody [EPR3861] (Abcam, ab92323) and goat anti-rabbit IgG conjugated with HRP (Sigma-Aldrich, A0545). To determine the cleavage of S proteins, 293T cells were transfected with 2 μL of lipofectamine 2000 (Life Technologies) in complex with 1 μg plasmid expressing the indicated S protein variant. Cells were harvested for western blot analysis 48 hours post transfection. Cells were permeabilized with PBS including 0.5% Triton X-100 (Sigma-Aldrich) at room temperature for 10 min, and detected by 1 μg/ml anti-Flag M2 antibody (Sigma-Aldrich, F1804) and goat anti-mouse IgG (Fab only) conjugated with HRP (Sigma-Aldrich, A9917).
..
References
Belouzard, Chu, Whittaker, Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.0809524106
Bertram, Heurich, Lavender, Gierer, Danisch et al., Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts, PloS one, doi:10.1371/journal.pone.0035876
Bo ¨ttcher, Matrosovich, Beyerle, Klenk, Garten et al., Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium, Journal of virology, doi:10.1128/JVI.01118-06
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, New England Journal of Medicine
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, MedRxiv, doi:10.1001/jama.2020.22240
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences, doi:10.3785/j.issn.1008-9292.2020.03.03
Coutard, Valle, De Lamballerie, Canard, Seidah et al., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral research, doi:10.1016/j.antiviral.2020.104742
Gautret, Lagier, Parola, Meddeb, Mailhe et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International journal of antimicrobial agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2012410
Glowacka, Bertram, Mu ¨ller, Soilleux, Pfefferle, Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response, Journal of virology, doi:10.1128/JVI.02232-10
Hasan, Paray, Hussain, Qadir, Attar et al., A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1754293
Hoffmann, Kleine-Weber, Schroeder, Kru ¨ger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Hu, Frieman, Insights from nanomedicine into chloroquine efficacy against COVID-19, Nature Nanotechnology, doi:10.1038/s41565-020-0674-9
Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochemical, doi:10.1016/j.bbrc.2004.08.085
Li, Greenough, Moore, Vasilieva, Somasundaran et al., Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2, Journal of virology, doi:10.1128/JVI.78.20.11429-11433.2004
Li, Moore, Vasilieva, Sui, Wong et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, doi:10.1038/nature02145
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell discovery, doi:10.1038/s41421-019-0132-8
Matsuyama, Nagata, Shirato, Kawase, Takeda et al., Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2, Journal of virology, doi:10.1128/JVI.01542-10
Millet, Whittaker, Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.1407087111
Ou, Liu, Lei, Li, Mi et al., Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nature communications, doi:10.1038/s41467-019-13993-7
Qi, Qian, Zhang, Zhang, Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses, Biochemical and biophysical research communications, doi:10.1016/j.bbrc.2020.03.044
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, Jama, doi:10.1001/jama.2020.6019
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases, The Lancet infectious diseases, doi:10.1016/s1473-3099%2803%2900806-5
Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, The Lancet infectious diseases, doi:10.1016/S1473-3099%2806%2970361-9
Shang, Ye, Shi, Wan, Luo et al., Structural basis of receptor recognition by SARS-CoV-2, Nature, doi:10.1038/s41586-020-2179-y
Shirato, Kawase, Matsuyama, Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2, Journal of virology, doi:10.1128/JVI.01890-13
Shirato, Kawase, Matsuyama, Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry, Virology, doi:10.1016/j.virol.2017.11.012
Simmons, Gosalia, Rennekamp, Reeves, Diamond et al., Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.0505577102
Spinelli, Pellino, COVID-19 pandemic: perspectives on an unfolding crisis, The British Journal of Surgery
Sungnak, Huang, Be ´cavin, Berg, Queen et al., SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nature medicine, doi:10.1038/s41591-020-0868-6
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virology journal, doi:10.1186/1743-422X-2-69
Walls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell research, doi:10.1038/s41422-020-0282-0
Wrobel, Benton, Xu, Roustan, Martin et al., SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects, Nature Structural & Molecular Biology
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clinical Infectious Diseases
Zhang, Jackson, Mou, Ojha, Rangarajan et al., The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity, bioRxiv, doi:10.1101/2020.06.12.148726
Zhang, Penninger, Li, Zhong, Slutsky, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, doi:10.1007/s00134-020-05985-9
Zhao, Zhao, Wang, Zhou, Ma et al., Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov
Zhou, Vedantham, Lu, Agudelo, Carrion R Jr et al., Protease inhibitors targeting coronavirus and filovirus entry, Antiviral research, doi:10.1016/j.antiviral.2015.01.011
Ziegler, Allon, Nyquist, Mbano, Miao et al., SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues, Cell, doi:10.1016/j.cell.2020.04.035
Zou, Chen, Zou, Han, Hao et al., Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Frontiers of medicine, doi:10.1007/s11684-020-0754-0
DOI record:
{
"DOI": "10.1371/journal.ppat.1009212",
"ISSN": [
"1553-7374"
],
"URL": "http://dx.doi.org/10.1371/journal.ppat.1009212",
"abstract": "<jats:p>Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This compound is known to interfere with endosomal acidification necessary to the proteolytic activity of cathepsins. Following receptor binding and endocytosis, cathepsin L can cleave the SARS-CoV-1 and SARS-CoV-2 spike (S) proteins, thereby activating membrane fusion for cell entry. The plasma membrane-associated protease TMPRSS2 can similarly cleave these S proteins and activate viral entry at the cell surface. Here we show that the SARS-CoV-2 entry process is more dependent than that of SARS-CoV-1 on TMPRSS2 expression. This difference can be reversed when the furin-cleavage site of the SARS-CoV-2 S protein is ablated or when it is introduced into the SARS-CoV-1 S protein. We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone. These studies identify functional differences between SARS-CoV-1 and -2 entry processes, and provide a mechanistic explanation for the limited <jats:italic>in vivo</jats:italic> utility of hydroxychloroquine as a treatment for COVID-19.</jats:p>",
"author": [
{
"affiliation": [],
"family": "Ou",
"given": "Tianling",
"sequence": "first"
},
{
"affiliation": [],
"family": "Mou",
"given": "Huihui",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhang",
"given": "Lizhou",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ojha",
"given": "Amrita",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Choe",
"given": "Hyeryun",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-2990-5319",
"affiliation": [],
"authenticated-orcid": true,
"family": "Farzan",
"given": "Michael",
"sequence": "additional"
}
],
"container-title": "PLOS Pathogens",
"container-title-short": "PLoS Pathog",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"www.plospathogens.org"
]
},
"created": {
"date-parts": [
[
2021,
1,
19
]
],
"date-time": "2021-01-19T18:44:20Z",
"timestamp": 1611081860000
},
"deposited": {
"date-parts": [
[
2021,
1,
29
]
],
"date-time": "2021-01-29T18:48:53Z",
"timestamp": 1611946133000
},
"editor": [
{
"affiliation": [],
"family": "Lee",
"given": "Benhur",
"sequence": "first"
}
],
"indexed": {
"date-parts": [
[
2024,
5,
11
]
],
"date-time": "2024-05-11T15:55:50Z",
"timestamp": 1715442950445
},
"is-referenced-by-count": 158,
"issue": "1",
"issued": {
"date-parts": [
[
2021,
1,
19
]
]
},
"journal-issue": {
"issue": "1",
"published-online": {
"date-parts": [
[
2021,
1,
19
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
1,
19
]
],
"date-time": "2021-01-19T00:00:00Z",
"timestamp": 1611014400000
}
}
],
"link": [
{
"URL": "https://dx.plos.org/10.1371/journal.ppat.1009212",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "340",
"original-title": [],
"page": "e1009212",
"prefix": "10.1371",
"published": {
"date-parts": [
[
2021,
1,
19
]
]
},
"published-online": {
"date-parts": [
[
2021,
1,
19
]
]
},
"publisher": "Public Library of Science (PLoS)",
"reference": [
{
"article-title": "COVID-19 pandemic: perspectives on an unfolding crisis",
"author": "A Spinelli",
"journal-title": "The British Journal of Surgery",
"key": "ppat.1009212.ref001",
"year": "2020"
},
{
"article-title": "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review",
"author": "JM Sanders",
"first-page": "1824",
"issue": "18",
"journal-title": "Jama",
"key": "ppat.1009212.ref002",
"volume": "323",
"year": "2020"
},
{
"article-title": "Observational study of hydroxychloroquine in hospitalized patients with Covid-19",
"author": "J Geleris",
"journal-title": "New England Journal of Medicine",
"key": "ppat.1009212.ref003",
"year": "2020"
},
{
"article-title": "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19",
"author": "J Chen",
"first-page": "215",
"issue": "2",
"journal-title": "Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences",
"key": "ppat.1009212.ref004",
"volume": "49",
"year": "2020"
},
{
"article-title": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial",
"author": "Z Chen",
"journal-title": "MedRxiv",
"key": "ppat.1009212.ref005",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
"author": "P Gautret",
"doi-asserted-by": "crossref",
"first-page": "105949",
"journal-title": "International journal of antimicrobial agents",
"key": "ppat.1009212.ref006",
"year": "2020"
},
{
"article-title": "A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19",
"author": "DR Boulware",
"journal-title": "New England Journal of Medicine",
"key": "ppat.1009212.ref007",
"year": "2020"
},
{
"article-title": "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)",
"author": "X Yao",
"journal-title": "Clinical Infectious Diseases",
"key": "ppat.1009212.ref008",
"year": "2020"
},
{
"article-title": "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro",
"author": "J Liu",
"first-page": "1",
"issue": "1",
"journal-title": "Cell discovery",
"key": "ppat.1009212.ref009",
"volume": "6",
"year": "2020"
},
{
"DOI": "10.1038/s41422-020-0282-0",
"article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
"author": "M Wang",
"doi-asserted-by": "crossref",
"first-page": "269",
"issue": "3",
"journal-title": "Cell research",
"key": "ppat.1009212.ref010",
"volume": "30",
"year": "2020"
},
{
"DOI": "10.1186/1743-422X-2-69",
"article-title": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread",
"author": "MJ Vincent",
"doi-asserted-by": "crossref",
"first-page": "69",
"issue": "1",
"journal-title": "Virology journal",
"key": "ppat.1009212.ref011",
"volume": "2",
"year": "2005"
},
{
"DOI": "10.1016/j.bbrc.2004.08.085",
"article-title": "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine",
"author": "E Keyaerts",
"doi-asserted-by": "crossref",
"first-page": "264",
"issue": "1",
"journal-title": "Biochemical and biophysical research communications",
"key": "ppat.1009212.ref012",
"volume": "323",
"year": "2004"
},
{
"DOI": "10.1038/s41565-020-0674-9",
"article-title": "Insights from nanomedicine into chloroquine efficacy against COVID-19",
"author": "TY Hu",
"doi-asserted-by": "crossref",
"first-page": "247",
"issue": "4",
"journal-title": "Nature Nanotechnology.",
"key": "ppat.1009212.ref013",
"volume": "15",
"year": "2020"
},
{
"DOI": "10.1016/S1473-3099(03)00806-5",
"article-title": "Effects of chloroquine on viral infections: an old drug against today's diseases",
"author": "A Savarino",
"doi-asserted-by": "crossref",
"first-page": "722",
"issue": "11",
"journal-title": "The Lancet infectious diseases",
"key": "ppat.1009212.ref014",
"volume": "3",
"year": "2003"
},
{
"DOI": "10.1073/pnas.0505577102",
"article-title": "Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry",
"author": "G Simmons",
"doi-asserted-by": "crossref",
"first-page": "11876",
"issue": "33",
"journal-title": "Proceedings of the National Academy of Sciences",
"key": "ppat.1009212.ref015",
"volume": "102",
"year": "2005"
},
{
"article-title": "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV",
"author": "X Ou",
"first-page": "1",
"issue": "1",
"journal-title": "Nature communications",
"key": "ppat.1009212.ref016",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.1038/nature02145",
"article-title": "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus",
"author": "W Li",
"doi-asserted-by": "crossref",
"first-page": "450",
"issue": "6965",
"journal-title": "Nature",
"key": "ppat.1009212.ref017",
"volume": "426",
"year": "2003"
},
{
"DOI": "10.1007/s00134-020-05985-9",
"article-title": "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target",
"author": "H Zhang",
"doi-asserted-by": "crossref",
"first-page": "586",
"issue": "4",
"journal-title": "Intensive care medicine",
"key": "ppat.1009212.ref018",
"volume": "46",
"year": "2020"
},
{
"DOI": "10.1038/s41586-020-2179-y",
"article-title": "Structural basis of receptor recognition by SARS-CoV-2",
"author": "J Shang",
"doi-asserted-by": "crossref",
"first-page": "221",
"issue": "7807",
"journal-title": "Nature",
"key": "ppat.1009212.ref019",
"volume": "581",
"year": "2020"
},
{
"DOI": "10.1073/pnas.0809524106",
"article-title": "Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites",
"author": "S Belouzard",
"doi-asserted-by": "crossref",
"first-page": "5871",
"issue": "14",
"journal-title": "Proceedings of the National Academy of Sciences",
"key": "ppat.1009212.ref020",
"volume": "106",
"year": "2009"
},
{
"article-title": "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein",
"author": "AC Walls",
"journal-title": "Cell",
"key": "ppat.1009212.ref021",
"year": "2020"
},
{
"DOI": "10.1128/JVI.01542-10",
"article-title": "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2",
"author": "S Matsuyama",
"doi-asserted-by": "crossref",
"first-page": "12658",
"issue": "24",
"journal-title": "Journal of virology",
"key": "ppat.1009212.ref022",
"volume": "84",
"year": "2010"
},
{
"DOI": "10.1128/JVI.02232-10",
"article-title": "Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response",
"author": "I Glowacka",
"doi-asserted-by": "crossref",
"first-page": "4122",
"issue": "9",
"journal-title": "Journal of virology",
"key": "ppat.1009212.ref023",
"volume": "85",
"year": "2011"
},
{
"article-title": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor",
"author": "M Hoffmann",
"journal-title": "Cell",
"key": "ppat.1009212.ref024",
"year": "2020"
},
{
"article-title": "A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin",
"author": "A Hasan",
"first-page": "1",
"journal-title": "Journal of Biomolecular Structure and Dynamics",
"key": "ppat.1009212.ref025",
"volume": "2020"
},
{
"DOI": "10.1371/journal.pone.0035876",
"article-title": "Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts",
"author": "S Bertram",
"doi-asserted-by": "crossref",
"issue": "4",
"journal-title": "PloS one",
"key": "ppat.1009212.ref026",
"volume": "7",
"year": "2012"
},
{
"DOI": "10.1038/s41591-020-0868-6",
"article-title": "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes",
"author": "W Sungnak",
"doi-asserted-by": "crossref",
"first-page": "681",
"issue": "5",
"journal-title": "Nature medicine",
"key": "ppat.1009212.ref027",
"volume": "26",
"year": "2020"
},
{
"article-title": "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues",
"author": "CG Ziegler",
"journal-title": "Cell",
"key": "ppat.1009212.ref028",
"year": "2020"
},
{
"article-title": "Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov",
"author": "Y Zhao",
"journal-title": "BioRxiv",
"key": "ppat.1009212.ref029",
"year": "2020"
},
{
"article-title": "Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection",
"author": "X Zou",
"first-page": "1",
"journal-title": "Frontiers of medicine",
"key": "ppat.1009212.ref030",
"volume": "2020"
},
{
"article-title": "Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses",
"author": "F Qi",
"journal-title": "Biochemical and biophysical research communications",
"key": "ppat.1009212.ref031",
"year": "2020"
},
{
"DOI": "10.1128/JVI.01890-13",
"article-title": "Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2",
"author": "K Shirato",
"doi-asserted-by": "crossref",
"first-page": "12552",
"issue": "23",
"journal-title": "Journal of virology",
"key": "ppat.1009212.ref032",
"volume": "87",
"year": "2013"
},
{
"DOI": "10.1128/JVI.01118-06",
"article-title": "Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium",
"author": "E Böttcher",
"doi-asserted-by": "crossref",
"first-page": "9896",
"issue": "19",
"journal-title": "Journal of virology",
"key": "ppat.1009212.ref033",
"volume": "80",
"year": "2006"
},
{
"DOI": "10.1016/S1473-3099(06)70361-9",
"article-title": "New insights into the antiviral effects of chloroquine",
"author": "A Savarino",
"doi-asserted-by": "crossref",
"first-page": "67",
"issue": "2",
"journal-title": "The Lancet infectious diseases",
"key": "ppat.1009212.ref034",
"volume": "6",
"year": "2006"
},
{
"article-title": "The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity",
"author": "L Zhang",
"journal-title": "bioRxiv",
"key": "ppat.1009212.ref035",
"year": "2020"
},
{
"DOI": "10.1016/j.antiviral.2015.01.011",
"article-title": "Protease inhibitors targeting coronavirus and filovirus entry",
"author": "Y Zhou",
"doi-asserted-by": "crossref",
"first-page": "76",
"journal-title": "Antiviral research",
"key": "ppat.1009212.ref036",
"volume": "116",
"year": "2015"
},
{
"DOI": "10.1073/pnas.1407087111",
"article-title": "Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein",
"author": "JK Millet",
"doi-asserted-by": "crossref",
"first-page": "15214",
"issue": "42",
"journal-title": "Proceedings of the National Academy of Sciences",
"key": "ppat.1009212.ref037",
"volume": "111",
"year": "2014"
},
{
"DOI": "10.1016/j.virol.2017.11.012",
"article-title": "Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry",
"author": "K Shirato",
"doi-asserted-by": "crossref",
"first-page": "9",
"journal-title": "Virology",
"key": "ppat.1009212.ref038",
"volume": "517",
"year": "2018"
},
{
"DOI": "10.1016/j.antiviral.2020.104742",
"article-title": "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade",
"author": "B Coutard",
"doi-asserted-by": "crossref",
"first-page": "104742",
"journal-title": "Antiviral research",
"key": "ppat.1009212.ref039",
"volume": "176",
"year": "2020"
},
{
"article-title": "SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects.",
"author": "AG Wrobel",
"first-page": "1",
"journal-title": "Nature Structural & Molecular Biology",
"key": "ppat.1009212.ref040",
"volume": "2020"
},
{
"DOI": "10.1128/JVI.78.20.11429-11433.2004",
"article-title": "Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2",
"author": "W Li",
"doi-asserted-by": "crossref",
"first-page": "11429",
"issue": "20",
"journal-title": "Journal of virology",
"key": "ppat.1009212.ref041",
"volume": "78",
"year": "2004"
}
],
"reference-count": 41,
"references-count": 41,
"relation": {
"has-preprint": [
{
"asserted-by": "object",
"id": "10.1101/2020.07.22.216150",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://dx.plos.org/10.1371/journal.ppat.1009212"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1371/journal.ppat.corrections_policy",
"update-to": [
{
"DOI": "10.1371/journal.ppat.1009212",
"label": "New version",
"type": "new_version",
"updated": {
"date-parts": [
[
2021,
1,
29
]
],
"date-time": "2021-01-29T00:00:00Z",
"timestamp": 1611878400000
}
}
],
"volume": "17"
}